Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10331454" target="_blank" >RIV/00179906:_____/16:10331454 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/16:10331454
Result on the web
<a href="https://www.hindawi.com/journals/jir/2016/5380792/" target="_blank" >https://www.hindawi.com/journals/jir/2016/5380792/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1155/2016/5380792" target="_blank" >10.1155/2016/5380792</a>

Result language
angličtina
Original language name
Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients
Original language description
The presented article studies the role of selected inflammatory and anti-inflammatory serum markers of psoriatic patients in the pathogenesis of metabolic syndrome (MS) and psoriasis. The study is based on the comparison between the group of psoriatic patients (74) and the control group (65). Observed inflammatory and anti-inflammatory markers (C-reactive protein, adiponectin, leptin, resistin, and lipoprotein-associated phospholipase A2 - Lp-PLA2) are involved in both pathogenesis of MS and pathogenesis of psoriasis. The level of Lp-PLA2 indicates the presence of subclinical atherosclerosis (cardiovascular risk) in psoriatic patients.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FO - Dermatology and venereology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)